Steroid trials in the assessment of reversibility of air flow limitation: a survey of current clinical practice of chest physicians.
To evaluate how steroid trials are currently used in the assessment of reversibility of air flow limitation, a postal questionnaire was sent to 355 consultant members of the British Thoracic Society working in England and Wales; 253 questionnaires were returned (71% response rate). Two respondents did not undertake steroid trials; of the remaining 251, 75% prescribed 30-40 mg oral prednisolone, with the commonest treatment period being 2 weeks. A high dose steroid inhaler was sometimes used as an alternative by 31% of respondents. Although 71% of respondents made lung function measurements on several occasions before starting steroids and 76% made measurements during treatment, 78% assessed patients on only one occasion at the end of the trials to ascertain its outcome. Weight, blood pressure and glycosuria were measured less frequently after the steroid treatment compared to the pre-trial period. Blood glucose and serum electrolytes were infrequently measured both before and after treatment. Wide variations exist in steroid trial regimens and current practice may neither provide definitive evidence of treatment benefit nor an adequate safeguard for patients against potential side-effects.
Wiggins
J
J
Department of Respiratory Medicine, Westminster Hospital, London, U.K.
Feher
M D
MD
Lant
A F
AF
Collins
J V
JV
D002908:Chronic Disease; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008173:Lung Diseases, Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011239:Prednisolone / Q000627:therapeutic use*; D012123:Pulmonary Ventilation / Q000187:drug effects*; D012129:Respiratory Function Tests
D011239:Prednisolone